3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm Metastasis
1
Laryngeal Diseases
1
Genital Neoplasms, Male
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Docetaxel
171
Radiotherapy
144
Magnetic Resonance Spectroscopy
142
Leuprolide
112
Prednisone
108
enzalutamide
102
Radiosurgery
101
Abiraterone Acetate
94
Androgen Antagonists
91
Goserelin
83
bicalutamide
81
gallium 68 PSMA-11
70
Surveys and Questionnaires
63
apalutamide
57
Specimen Handling
56
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
55
Radiation
47
Gonadotropin-Releasing Hormone
45
Standard of Care
44
Biopsy
44
Brachytherapy
42
Radiotherapy, Intensity-Modulated
40
Blood Specimen Collection
40
darolutamide
39
abiraterone
39
cabazitaxel
35
Exercise
35
Carboplatin
33
Pluvicto
32
Triptorelin Pamoate
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms
×
Chemical Fractionation
×
Clear all
NCT02319239
2020-10-28
ESKO
Tampere University Hospital
Phase NA
Completed
80 enrolled